Simponi solution for injection is a human TNFa monoclonal antibody, golimumab.
Simponi was discovered and developed by Jansen Biotech as a treatment for inflammatory autoimmune diseases (involving TNFa) such as rheumatoid arthritis.
In July 2011, Jansen received marketing and manufacturing license of the product, after which Jansen and Mitsubishi started co-marketing the agent.
Jansan Taiwan will also be marketing Simponi solution for injection along with Mitsubishi, in Taiwan.